Achmea Investment Management B.V. Sells 30,386 Shares of Bristol-Myers Squibb Co (BMY)

Share on StockTwits

Achmea Investment Management B.V. lowered its position in Bristol-Myers Squibb Co (NYSE:BMY) by 17.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 142,124 shares of the biopharmaceutical company’s stock after selling 30,386 shares during the period. Achmea Investment Management B.V.’s holdings in Bristol-Myers Squibb were worth $8,818,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in Bristol-Myers Squibb by 7.2% in the second quarter. BlackRock Inc. now owns 111,913,559 shares of the biopharmaceutical company’s stock valued at $6,193,296,000 after acquiring an additional 7,517,623 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Bristol-Myers Squibb by 44.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 9,460,148 shares of the biopharmaceutical company’s stock valued at $587,287,000 after acquiring an additional 2,903,920 shares during the period. Janus Henderson Group PLC lifted its holdings in Bristol-Myers Squibb by 114.5% in the second quarter. Janus Henderson Group PLC now owns 6,922,917 shares of the biopharmaceutical company’s stock valued at $383,119,000 after acquiring an additional 3,695,485 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in Bristol-Myers Squibb by 2.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 6,283,205 shares of the biopharmaceutical company’s stock valued at $347,713,000 after acquiring an additional 172,417 shares during the period. Finally, Bank of Montreal Can lifted its holdings in Bristol-Myers Squibb by 13.9% in the third quarter. Bank of Montreal Can now owns 5,862,162 shares of the biopharmaceutical company’s stock valued at $363,924,000 after acquiring an additional 717,503 shares during the period. Hedge funds and other institutional investors own 72.54% of the company’s stock.

Shares of BMY stock opened at $53.39 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.40. The company has a market cap of $86.49 billion, a PE ratio of 17.74, a price-to-earnings-growth ratio of 1.48 and a beta of 1.08. Bristol-Myers Squibb Co has a 1-year low of $46.94 and a 1-year high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.18. The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. On average, sell-side analysts forecast that Bristol-Myers Squibb Co will post 3.88 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Investors of record on Friday, October 5th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 3.00%. The ex-dividend date of this dividend was Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.

A number of research analysts have issued reports on BMY shares. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. Jefferies Financial Group set a $58.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, July 15th. BMO Capital Markets reissued a “hold” rating on shares of Bristol-Myers Squibb in a report on Sunday, July 22nd. Credit Suisse Group boosted their price target on Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a report on Friday, July 27th. Finally, SunTrust Banks reissued a “buy” rating and issued a $67.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, July 31st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $62.48.

COPYRIGHT VIOLATION WARNING: “Achmea Investment Management B.V. Sells 30,386 Shares of Bristol-Myers Squibb Co (BMY)” was first posted by Macon Daily and is the property of of Macon Daily. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://macondaily.com/2018/11/11/achmea-investment-management-b-v-sells-30386-shares-of-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

See Also: Fundamental Analysis

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply